Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LSS | P48449 | 6/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | TP53 | P04637 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6429091 | 1.00 | MEN1 (0.43) | MEN1KMT2ALSSMAPTTP53 | |
| SCHEMBL5638296 | 0.92 | MAPT (0.47) | LSSMAPTTP53LMNA | |
| SCHEMBL6403814 | 0.92 | NLRP3 (0.41) | MEN1KMT2ALSSMAPTTP53 | |
| SCHEMBL6430242 | 0.92 | LSS (0.49) | MEN1KMT2ALSSMAPTTP53 | |
| SCHEMBL6398603 | 0.92 | LSS (0.49) | MEN1KMT2ALSSMAPTTP53 | |
| SCHEMBL6400289 | 0.92 | MAPT (0.41) | MEN1KMT2ALSSMAPTTP53 | |
| SCHEMBL5635668 | 0.91 | HRH3 (0.41) | MEN1KMT2ALSSMAPTTP53 | |
| SCHEMBL6406579 | 0.91 | LSS (0.40) | MEN1KMT2ALSSMAPTTP53 | |
| SCHEMBL6403927 | 0.90 | MAPT (0.40) | MEN1KMT2ALSSMAPTTP53 | |
| SCHEMBL6404825 | 0.89 | MAPT (0.40) | LSSMAPTTP53LMNARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. | 2005-08-25 | — | — | US | disclosed |
| US-20050020624-A1 | Dihydroindole and tetrahydroquinoline derivatives | AEBI JOHANNES (CH) | 2005-01-27 | — | — | US | disclosed |
| US-6844351-B1 | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 2005-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020624-A1 | Dihydroindole and tetrahydroquinoline derivatives | CYP46A1, LSS, CYP51A1 | MEN1 402/4885KMT2A 2451/4885LSS 2/4885 |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | HAVCR2, MAVS, ZC3HAV1 | MEN1 4832/4885KMT2A 2410/4885LSS 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.